open access

Vol 12, No 4 (2008)
Artykuły redakcyjne
Published online: 2008-09-01
Get Citation

PTH and arterial hypertension

Anna Bożek, Magdalena Pajda, Jerzy Chudek, Andrzej Więcek
Nadciśnienie tętnicze 2008;12(4):253-260.

open access

Vol 12, No 4 (2008)
Artykuły redakcyjne
Published online: 2008-09-01

Abstract

Parathormon (PTH) has been recognized as a potential factor in the etiopathogenesis of essential hypertension. The higher prevalence of arterial hypertention in primary hyperparathyroidism (pHPT) than in the general population and higher serum PTH concetration in patients with essential hypertensive are the only indirect evidence confirming this assumption. Infusion of PTH in man results in transient vasodilatation and increased urinary sodium excretion that gives evidence against its hypertensive effect. On the contrary, impaired endothelial function, proliferation of vascular smooth cells and heart hypertrophy may cause increase of blood pressure. Question concerning the role of PTH in the pathogenesis of arterial hypertension arises when excretory renal function, which is often impaired not only in patients with pHPT but also with arterial hypertension as a result of hypertensive nephropathy and ageing, is taken under consideration. It is important to remember about the negative consequences of long-term kidney exposition to increased PTH and serum calcium level in patients with pHPT. However, the role of PTH in the etiopathogenesis of arterial hypertension is still unclear, pHPT is undoubtedly associated with increased cardiovascular risk.
The aim of this critical review is to summarize current arguments concerning the relationship between PTH and arterial hypertension.

Abstract

Parathormon (PTH) has been recognized as a potential factor in the etiopathogenesis of essential hypertension. The higher prevalence of arterial hypertention in primary hyperparathyroidism (pHPT) than in the general population and higher serum PTH concetration in patients with essential hypertensive are the only indirect evidence confirming this assumption. Infusion of PTH in man results in transient vasodilatation and increased urinary sodium excretion that gives evidence against its hypertensive effect. On the contrary, impaired endothelial function, proliferation of vascular smooth cells and heart hypertrophy may cause increase of blood pressure. Question concerning the role of PTH in the pathogenesis of arterial hypertension arises when excretory renal function, which is often impaired not only in patients with pHPT but also with arterial hypertension as a result of hypertensive nephropathy and ageing, is taken under consideration. It is important to remember about the negative consequences of long-term kidney exposition to increased PTH and serum calcium level in patients with pHPT. However, the role of PTH in the etiopathogenesis of arterial hypertension is still unclear, pHPT is undoubtedly associated with increased cardiovascular risk.
The aim of this critical review is to summarize current arguments concerning the relationship between PTH and arterial hypertension.
Get Citation

Keywords

parathormon; primary hyperparathyroidism; parathyreoidectomy; arterial hypertension

About this article
Title

PTH and arterial hypertension

Journal

Arterial Hypertension

Issue

Vol 12, No 4 (2008)

Pages

253-260

Published online

2008-09-01

Bibliographic record

Nadciśnienie tętnicze 2008;12(4):253-260.

Keywords

parathormon
primary hyperparathyroidism
parathyreoidectomy
arterial hypertension

Authors

Anna Bożek
Magdalena Pajda
Jerzy Chudek
Andrzej Więcek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl